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Intensive lifestyle intervention provides rapid reduction
of serum fatty acid levels in women with severe obesity
without lowering omega-3 to unhealthy levels
C. Lin1,2, J. R. Andersen3,4, V. Våge4,5, T. Rajalahti1, S. A. Mjøs2 and O. M. Kvalheim2,3
What is already known about this subject
• High levels of the marine omega-3 fatty acids (FAs) reduce obesity-
induced inflammation and decrease the risk of developing conditions
related to metabolic syndrome.
• The weight loss process after bariatric surgery is accompanied by a
reduction of serum omega-3 levels.
What this study adds
• Intensive lifestyle intervention rapidly reduces elevated total FA serum
level and levels of saturated, monounsaturated and most omega-6 pol-
yunsaturated FAs.
• Weight loss during lifestyle intervention is not significantly associated
to change in FA levels and does not imply lowering of the omega-3 FAs
to unhealthy levels.
• Lower rate of weight loss accompanying lifestyle intervention com-
pared to bariatric surgery implies less input from fat deposits, which
are poor in omega-3. This makes lifestyle patients less exposed to
omega-3 shortage.
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Summary
Serum fatty acid (FA) levels were monitored in women with severe obesity during
intensive lifestyle intervention. At baseline, total FA levels and most individual
FAs were elevated compared to a matching cohort of normal and overweight
women (healthy controls). After 3 weeks of intensive lifestyle intervention, total
level was only 11–12% higher than in the healthy controls and with almost all
FAs being significantly lower than at baseline, but with levels of omega-3 being
similar to the healthy controls. This is contrary to observations for patients sub-
jected to bariatric surgery where omega-3 levels dropped to levels significantly
lower than in the lifestyle patients and healthy controls. During the next 3 weeks
of treatment, the FA levels in lifestyle patients were unchanged, while the weight
loss continued at almost the same rate as in the first 3 weeks. Multivariate
analysis revealed that weight loss and change of serum FA patterns were
unrelated outcomes of the intervention for lifestyle patients. For bariatric patients,
these processes were associated probably due to reduced dietary input and
increased input from the patients’ own fat deposits, causing a higher rate of weight
loss and simultaneous reduction of the ratio of serum eicosapentaenoic to
arachidonic acid.
Keywords: Bariatric surgery, intensive lifestyle intervention, multivariate analysis,
serum omega-3 fatty acids.
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Introduction
Many fatty acids (FAs), particularly the polyunsaturated
FAs (PUFAs), are crucial for metabolic health. After the
discovery of the inverse correlation between levels of
marine omega-3 FAs in plasma and incidence of cardiovas-
cular diseases (CVDs) (1), numerous investigations have
confirmed the importance of these PUFAs for reducing risk
of CVD (2–4) by redistributing the lipoprotein particles
towards a healthier pattern. The ratio of eicosapentaenoic
acid (EPA) to arachidonic acid (AA), EPA/AA, is regarded
as a marker of health, and the World Health Organization
recommends a level of 0.1–0.2, while in Japan a ratio of
0.2–0.3 is recommended (5).
Obesity may lead to inflammation of adipose tissue and
increased oxidative stress (6) accompanied by a reduction
in PUFAs. Micallef et al. (7) compared relative levels of
plasma PUFAs in adults with normal weight, overweight
and obesity. They observed a statistically significant inverse
relationship between weight status and percentage of EPA,
docosahexaenoic acid (DHA) and total omega-3 FAs,
i.e. α-linolenic acid (ALA) and docosapentaenoic acid
(DPA) in addition to EPA and DHA. However, the relative
levels of omega-3 FAs in serum can be lower in persons
with obesity even if the absolute levels are the same as in
those without obesity. This may happen if the total concen-
tration of FAs (TFAs) is significantly higher in subjects with
obesity than those without obesity. Thus, comparison of
serum FA levels should be based on absolute concentra-
tions. Using absolute concentrations, Lin et al. (8) observed
an inverse relationship between body mass index (BMI)
and omega-3 between a group of adults with severe obesity
(BMI ≥ 40 or 35 ≤ BMI ≤ 40 and presence of obesity-
related disease) selected for bariatric surgery and a control
group of healthy subjects with BMI ≤ 30. Not only was the
marine omega-3 FAs significantly lower in the subjects with
obesity but also the plant-derived omega-3 ALA was lower.
Furthermore, analysis of serum FAs 3 months after bariat-
ric surgery showed a further 30% decline in serum levels of
the omega-3 FAs and a 40% decline in EPA/AA from
already low preoperative levels. One year after surgery,
patients who had experienced laparoscopic sleeve gastrec-
tomy (LSG) (9,10) had concentrations close to preoperative
levels for EPA and EPA/AA, while patients who had been
exposed to biliopancreatic diversion with duodenal switch
(11) were still low on serum EPA and EPA/AA.
During weight loss, the FA levels in serum are influenced
both by dietary intake and input from the patient’s own fat
deposits. The FAs stored in the fat deposits are not optimal
from a nutritional point of view. ALA and DHA constitute
approximately 0.7–1.1% and 0.1-0.2%, respectively, of
adipose tissue, while EPA is only present in minute
amounts (12,13). If the observed reduction in omega-3
levels after bariatric surgery is a response to the weight loss
process accompanying surgery, a similar reduction may
also occur in subjects undergoing intensive lifestyle inter-
ventions. If this is the case, the patients may need omega-3
supplements during treatment. Thus, the primary aim of
this work was to reveal possible changes in serum FA pat-
terns during intensive lifestyle intervention. A secondary
objective was to reveal possible differences in total FA level
between the cohort of patients with obesity during lifestyle
treatment and matching cohorts of healthy subjects and
patients subjected to bariatric surgery.
Methods
Participants
Thirty-one women from the Fjord region of Western Nor-
way were selected for an intensive lifestyle intervention
focusing on a high-fibre low-fat reduced-energy Nordic
diet, increased physical activity (10 h per week organized
sessions plus individual sessions) and cognitive behaviour
therapy (14). Inclusion criteria for lifestyle patients were
age 18–60 years, BMI ≥ 40 or BMI ≥ 35 and the presence
of obesity-related disease. Exclusion criteria were preg-
nancy, heart disease, drug or alcohol abuse, bariatric sur-
gery and mental disorder or physical impairment. The
treatment included four periods of enrolment at the Red
Cross Haugland Rehabilitation Center (RCHRC), but the
present work describes only the results during the first
enrolment of 6 weeks as this was the period where signifi-
cant changes occurred in FA profiles. A control group of
45 healthy women was included in our study design. Inclu-
sion criteria were age 18–60 years and BMI in the interval
18.5–30. Exclusion criteria for healthy controls were preg-
nancy, smoking, drug abuse, use of lipid-lowering drugs
and established CVD, type 2 diabetes and cancer. A second
control group consisted of 18 adults measured 3 months
after LSG. Before being discharged from hospital, the bari-
atric patients were recommended a diet of small protein-
rich meals, to avoid sugar and sugar-containing products,
to use a multivitamin supplement and 1 g of calcium on
daily basis during the first year after surgery. Exclusion cri-
teria for bariatric patients were alcohol or drug abuse and
active psychosis. Three months after surgery, one of the
17 subjects was on lipid-lowering drugs and was excluded,
but none showed signs of type 2 diabetes. The group
included three men and 14 women. Men and women in the
bariatric group had similar FA profiles, and the men were
included in order to obtain a larger sample size. Written
informed consent was obtained for each participant. The
study was approved by the Regional Committee for Medi-
cal Research Ethics in southern Norway (reference num-
bers: 2009/2174 and 2010/3224) and was conducted in
accordance with the WMA Declaration of Helsinki and its
amendments.
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Three lifestyle patients were excluded due to use of lipid-
lowering drugs, and two were excluded because of type 2
diabetes. Blood samples were missing for two women at
baseline and for one woman after intervention. For another
patient, the weight was only available at baseline. This pro-
vided 24 lifestyle patients at baseline, 23 for comparing dif-
ferent sampling points during treatment and 25 for
comparing the patients with the healthy controls and bari-
atric patients 3 and 6 weeks into the lifestyle intervention.
Anthropometric and standard blood variables
Table 1 provides mean  standard deviation at baseline
for some commonly measured variables. BMI for lifestyle
patients after 3 and 6 weeks of enrolment at RCHRC was
40.5  5.9 and 39.7  5.7 kg/m2 (N = 23), respectively,
and 37.5  3.6 kg/m2 (N = 17) for bariatric patients
3 months after surgery. Weight for lifestyle patients at
baseline and after 3 and 6 weeks were 116.5  16.5,
113.6  16.0 and 111.3  15.6 kg, respectively.
Blood sampling and measurement of fatty acid
profiles
Blood samples for lifestyle patients were collected at enrol-
ment (baseline) and after 3 and 6 weeks of treatment. For
bariatric patients, samples were taken just before and
3 months after surgery. All samples were taken in the
morning after overnight fasting. Serum was obtained
according to a standardized protocol (17) and stored
at −80C.
The serum samples were prepared and analysed by
minor modifications of the procedure described in Lin et al.
(17). Total amounts of 18 FAs in each sample were quanti-
fied as μg per gram sample.
Univariate statistical analysis
Univariate comparisons of the FA profiles of the lifestyle
patients at the three sampling points during their first
enrolment at RCHRC were performed using the Wilcoxon
sign-rank (WSR) test (15). The P-values were corrected for
multiple testing by means of a false discovery rate (FDR)
according to Benjamini and Hochberg (18). Univariate
comparisons of lifestyle patients with either healthy con-
trols or bariatric patients were performed by means of the
Wilcoxon-Mann–Whitney (WMW) rank sum test (15,16)
corrected for multiple testing by means of FDR. The uni-
variate probabilities were calculated by means of Matlab
R2013b (MathWorks, Natick, Massachusetts, USA).
Multivariate data analysis
For the lifestyle patients, multivariate comparisons of
serum FA profiles at baseline with profiles after 3 weeks of
treatment were carried out using partial least squares dis-
criminant analysis (19). BMI was included in the analysis
in order to assess possible associations between changes in
BMI and FA profiles. Post-processing by target projection
(20) was performed to obtain the discriminatory FA pat-
tern that could be quantitatively displayed as a selectivity
ratio (SR) plot (21,22). This display shows an impact on
individual FAs, with confidence limits calculated by
repeated double cross validation (23) and if an FA
increases or decreases from one sampling point to another.
A similar analysis was carried out for bariatric patients to
compare FA profiles before and after surgery. Due to large
differences in amounts of the individual FAs, the variations
in FAs were standardized to unit variance prior to the mul-
tivariate analysis. The analysis was carried out by means of
the commercial software package Sirius (Pattern Recogni-
tion Systems AS, Bergen, Norway).
Table 1 Mean and standard deviation for anthropometric variables and standard blood variables for healthy controls, lifestyle and bariatric patients at
baseline. pWMW are the P-values calculated from the nonparametric Wilcoxon-Mann–Whitney (WMW) rank sum test (15,16) for comparing lifestyle and
bariatric patients
Variable Healthy
controls (N = 45)
Lifestyle
patients (N = 23)
Bariatric
patients (N = 17)
Lifestyle
vs. bariatric pWMW
Age 40.4  10.6 43.1  11.3 43.1  12.4 0.95
Weight (kg) 65.6  6.9 116.5  16.5
Body mass index (kg m−2) 23.2  2.2 41.5  6.1 45.1  3.4 0.05
Fat mass (kg) 18.5  5.2 58.2  11.3
Fat percent 27.7  5.3 49.5  3.3
Total cholesterol (mmol L−1) 5.1  1.1 5.2  1.2 (N = 21) 5.0  1.0 0.91
Low-density lipoprotein cholesterol
(mmol L−1)
3.1  1.0 3.7  1.1 (N = 21)
High-density lipoprotein cholesterol
(mmol L−1)
1.6  0.3 1.3  0.3 (N = 21) 1.1  0.3 0.12
Triglycerides (mmol L−1) 0.8  0.3 1.2  0.5 (N = 21) 1.5  0.5 (N = 16) 0.08
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Results
Fatty acid profiles in lifestyle patients vs. healthy
controls
At baseline, the TFA serum level is approximately 45%
higher in the lifestyle patients than in the healthy controls
(Table 2). The WMW rank sum test, after correcting for
multiple testing by FDR, shows that the differences in med-
ians for the two groups are statistically significant for
almost all FAs. Thus, at P = 0.05, only 14:0, EPA, DPA
and the EPA/AA ratio obey the null hypothesis of equal
medians, while at P = 0.01, the omega-3 FAs, ALA and
DHA also have similar medians.
Change in fatty acid profiles after intensive
lifestyle intervention
Table 3 shows the medians of the individual FAs for the
lifestyle patients at baseline (visit 1) and after 3 weeks of
treatment (visit 2). The P-values from the WSR test, cor-
rected for multiple testing by FDR, show significant
changes in median at P = 0.01 for all the saturated FAs.
The omega-3 FAs show different behaviour after 3 weeks
of lifestyle treatment. Thus, ALA and DPA are significantly
reduced from baseline at P = 0.01, while EPA is reduced at
P = 0.05, although borderline and DHA show no signifi-
cant changes. The EPA/AA ratio is also not significantly
changed from baseline. The levels of the monounsaturated
C16 and C18 omega-7 and omega-9 FAs are significantly
reduced from baseline except for 18:1 n-7. The essential
omega-6 FA, linoleic acid (LA) shows reduction at
P = 0.01. Actually, all the omega-6 FAs except AA show
reduction from baseline at P = 0.01 (Table 3).
The changes in each FA from baseline are displayed as
SRs in an SR plot. The plot is obtained from a multivariate
discriminant analysis with Visit No. as the dependent vari-
able. The discriminating information of each FA is quanti-
tatively displayed in the SR plot. A value of zero within the
confidence limits, which correspond to P = 0.05, means
that the FA carries no discriminating information. The
higher the SR is for an FA, the larger the discriminating
ability is for that FA and the larger the change is from visit
1 to 2. The FAs with a positive sign are increasing in con-
centration from baseline level, while a negative sign implies
reduction from baseline level. Figure 1 shows that all the
FAs are significantly reduced during lifestyle treatment
except 18:1 n-7, EPA, 24:1 n-9 (nervonic acid), DHA and
the EPA/AA ratio, which are unchanged. The largest
change is observed for the long-chain saturated FAs with
24 and 22 carbons followed by the saturated FAs 14:0 and
18:0 and omega-6 FAs, LA and dihomo-γ-linolenic acid
Table 2 Univariate statistical measures calculated for women with severe obesity selected for intensive lifestyle intervention (BMI ≥ 35 kg m−2) and a
matching cohort of healthy controls (BMI ≤ 30 kg m−2). Medians, minimum and maximum values are given in units of μg per g sample. pWMW are the
P-values calculated from the nonparametric WMW rank sum test (15,16). Asterisks (* and **) imply significance at P = 0.05 (pWMW = 0.04) and P = 0.01
(pWMW = 0.007), respectively, after correcting for multiple testing by false discovery rate (18)
Fatty acid Patients, BMI ≥ 35 kg m−2 (N = 24) Healthy controls, BMI ≤ 30 kg m−2 (N = 45)
Median Minimum Maximum Median Minimum Maximum pWMW
14:0 46.0 12.0 97.6 38.4 13.1 93.3 0.142
16:0 1252 545.5 2101 801.5 534.8 1343.5 5.6 × 10−6**
16:1 n-9 22.4 8.3 48.6 12.6 5.1 30.4 1.1 × 10−4**
16:1 n-7 141.1 43.6 292.3 69.9 28.7 196.9 3.2 × 10−6**
18:0 420.5 164.7 633.0 277.6 175.9 467.1 4.6 × 10−5**
18:1 n-9 1104 429.3 2192 674.5 481.9 1375.4 1.3 × 10−5**
18:1 n-7 80.4 37.7 177.5 48.9 31.3 117.0 2.9 × 10−7**
18:2 n-6 (LA) 1500 688.7 2327 1209.0 664.9 1777.3 3.9 × 10−4**
18:3 n-3 (ALA) 36.2 16.3 105.7 27.5 7.7 54.7 0.014*
20:3 n-6 (DGLA) 89.4 17.1 191.8 51.4 19.8 125.0 2.2 × 10−5**
20:4 n-6 (AA) 338.2 159.8 897.6 234.3 133.6 435.4 1.2 × 10−5**
22:0 50.5 19.0 88.7 34.3 20.1 65.0 3.7 × 10−5**
20:5 n-3 (EPA) 63.1 12.7 172.5 52.3 13.9 261.8 0.335
24:0 44.0 17.0 66.8 35.8 19.0 72.5 3.3 × 10−3**
22:5 n-6 6.0 3.0 15.7 3.9 0.0 18.3 8.6 × 10−4**
24:1 n-9 88.4 51.5 181.2 62.7 35.0 108.3 2.0 × 10−5**
22:5 n-3 (DPA) 38.2 18.5 63.7 32.0 21.6 56.4 0.064
22:6 n-3 (DHA) 130.4 81.1 277.6 111.1 58.9 319.1 0.035*
TFA 5531 2544.8 9261 3811.2 2403.7 6236.3 9.5 × 10−6**
EPA/AA 0.180 0.063 0.523 0.223 0.065 0.937 0.174
AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; TFA, total concentration of fatty acids; WMW, Wilcoxon-Mann–Whitney.
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(DGLA). After these FAs, the FAs DPA, 22:5 n-6, 16:0 and
TFA follow. Comparison of the SR values with the P-
values in Table 3 (visit 1 and visit 2) shows that the rank-
ing of FAs according to discriminatory information from
Table 3 Medians, in units of μg per g sample, are provided for serum FAs from women with obesity (BMI ≥ 35 kg m−2) at baseline (visit 1) and after
3 weeks of intensive lifestyle intervention (visit 2). The P-values comparing the FA levels at visits 1 and 2 are calculated from the nonparametric WSR test
(15). The nonparametric WMW rank sum test (15,16) is used to compare serum FA levels in the patients at visit 2 with levels in a cohort of healthy women
(BMI ≤ 30 kg m−2) and levels 3 months after surgery in a cohort of patients that has experienced LSG (8). The omega-3 DPA and omega-6 22:5 n-6 were
not quantifiable in the bariatric patients due to co-elution with major interferents. Asterisks (* and **) after a P-value imply significance at P = 0.05
(pWSR = 0.0375, pWMW = 0.0225 and pWMW = 0.011 for comparison of lifestyle patients at visit 1 and 2 and lifestyle patients at visit 2 with healthy and
LSG patients, respectively) and P = 0.01 (pWSR = 0.0065, pWMW = 0.004 and pWMW = 5.6 × 10−4 for comparison with lifestyle patients at visit 1 and 2
and lifestyle patients at visit 2 with healthy and LSG patients, respectively), respectively, after correcting for multiple testing by means of false discovery
rate (18)
FA Lifestyle patients (N = 23) Lifestyle patients at visit 2 (N = 25)
Medians Healthy controls (N = 45) LSG patients (N = 17)
Visit 1 Visit 2 pWSR Median pWMW Median pWMW
14:0 43.6 30.9 2.6 × 10−4** 38.4 0.028 23.4 0.174
16:0 1226 989.6 3.2 × 10−3** 801.5 1.7 × 10−3** 890.1 0.249
16:1 n-9 21.6 17.6 5.1 × 10−3** 12.6 3.5 × 10−3** 13.1 0.061
16:1 n-7 137.9 122.1 7.4 × 10−3* 69.9 4.7 × 10−5** 85.5 0.271
18:0 418.9 288.4 2.6 × 10−4** 277.6 0.352 254.3 0.036
18:1 n-9 1084 869.0 4.3 × 10−3** 674.5 7.2 × 10−4** 838.4 0.608
18:1 n-7 79.3 81.2 0.201 48.9 3.2 × 10−7** 65.2 0.398
18:2 n-6 (LA) 1512 1195 6.6 × 10−4** 1209 0.902 955.2 3.0 × 10−3*
18:3 n-3 (ALA) 37.7 25.5 2.4 × 10−3** 27.5 0.835 13.2 3.0 × 10−4**
20:3 n-6 (DGLA) 89.1 54.6 9.9 × 10−5** 51.4 0.220 42.4 0.073
20:4 n-6 (AA) 343.7 320.6 0.068 234.3 1.1 × 10−4** 308.3 0.798
22:0 50.3 33.1 4.6 × 10−5** 34.3 0.096 32.0 0.838
20:5 n-3 (EPA) 62.3 51.5 0.033* 52.3 0.825 27.7 1.6 × 10−3*
24:0 43.1 29.3 5.2 × 10−5** 35.8 2.5 × 10−5** 31.4 0.573
22:5 n-6 6.0 4.7 1.1 × 10−3** 3.9 0.384 Not available
24:1 n-9 90.0 81.5 0.738 62.7 1.6*10−7** 76.4 0.200
22:5 n-3 (DPA) 38.0 31.7 3.5 × 10−3** 32.0 0.286 Not available
22:6 n-3 (DHA) 121.8 134.8 0.543 111.1 0.043 93.8 0.023
TFA 5514 4379 1.6 × 10−3** 3811 8.4 × 10−3* 3836 0.026
EPA/AA 0.179 0.172 0.068 0.223 0.062 0.084 1.8 × 10−3*
AA, arachidonic acid; ALA, α-linolenic acid; BMI, body mass index; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; LA, linoleic acid; LSG, laparoscopic sleeve gastrectomy; TFA, total concentration of









































































































Figure 1 This figure shows the multivariate
pattern of change caused by the first 3 weeks
of lifestyle treatment. This selectivity ratio plot
(21,22) quantifies impact of 3 weeks of lifestyle
treatment on changes in absolute levels of
serum fatty acids and body mass index.
Confidence bounds shown on bars
correspond to two standard deviations.
Negative bar implies reduction, while positive
bar implies increase of variable after treatment.
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these two measures, from multivariate and univariate
methods, respectively, are in excellent agreement. How-
ever, some FAs are amplified in importance by the multi-
variate approach, e.g. 24:0, due to their correlation to the
multivariate pattern of discrimination, while some are wea-
kened, e.g. DGLA, compared to the ranking according to
P-values from the univariate comparison of medians at
baseline and after 3 weeks of lifestyle treatment. Note also
that AA, which was on the borderline of being significant
at P = 0.05 in the univariate comparison, is still borderline
but significant according to the multivariate analysis.
BMI was included in the multivariate analysis but shows
no associations to the changes in FA patterns (Fig. 1). Thus,
although the changes in BMI and FA pattern are both
caused by the lifestyle intervention, they appear to be unre-
lated outcomes of the intervention (Fig. 1).
Black bars show the starting point (score) at baseline for
patients on the multivariate scale described by the change
in FA pattern from visit 1 to 2 (Fig. 2), while the neigh-
bouring grey bar at the right shows the positions (score)
for the same patients after 3 weeks of lifestyle change. The
difference between grey and black bars for a patient quan-
tifies the improvement on the multivariate FA profile
(Fig. 1). We observe that all patients show improvements
in their FA profiles during the first 3 weeks of intensive life-
style intervention, implying a reduction in serum levels of
most FAs, as displayed in Fig. 1. As expected, both the
starting point and the response to the lifestyle intervention
vary substantially from patient to patient.
Comparison of lifestyle patients with healthy
controls after 3 weeks of treatment
Use of the WSR test revealed no statistically significant
changes in FA levels from visit 2 (3 weeks into interven-
tion) to visit 3 (6 weeks into intervention) for the lifestyle
patients (not shown). We then compared levels in lifestyle
patients at visit 2 with the healthy controls. Table 3 shows
the results of the WMW test. After correcting for multiple
testing, the saturated FA 16:0 and the monounsaturated
omega-7 and omega-9 FAs with 16 and 18 carbons in the
chain are higher in the patients than the healthy subjects at
P = 0.01. However, both the essential FAs, LA and ALA,
possess the same serum levels in lifestyle patients as in
healthy subjects, as do the omega-3 EPA, DPA and DHA
and the EPA/AA ratio. Even if the TFA serum levels have
decreased by approximately 20% on average from baseline
to visit 2 for the patients, the levels are still higher than in
healthy subjects at P = 0.05. Nervonic acid and AA are
both higher in patients at P = 0.01. After 3 weeks of life-
style treatment, the only FA that is significantly lower in
concentration in patients compared to healthy controls is
the saturated long-chain FA 24:0 (P < 0.01).
Comparison of lifestyle patients with bariatric
patients
The lifestyle patients at visit 2 are also compared with a
group of bariatric patients subjected to LSG surgery, which
creates gastric restriction by reducing the gastric volume.
Comparison of FA serum levels in lifestyle patients after
3 weeks of intensive lifestyle intervention with levels in a
matching group of bariatric patients 3 months after surgery
(Table 3, last column) reveals that only LA and the omega-
3 FAs, ALA, EPA and EPA/AA are significantly different at
P = 0.05, taking into account the effect of multiple testing
on probability levels. These FAs are all lower in the bariat-
ric patients.
To investigate a possible association between change in
FA pattern and weight loss as measured by BMI, multivari-
ate discriminant analysis was performed for bariatric
patients at, before and 3 months after surgery (Fig. 3).
The difference from Fig. 1 is striking. After LSG surgery,
reduction in BMI is the dominating discriminating feature,
but this reduction is associated with a reduction of EPA

















Figure 2 This figure shows the changes in
fatty acid profiles on the multivariate pattern
displayed in Fig. 1 as positions (scores) of
lifestyle patients (N = 23) at baseline (black
bars) and after 3 weeks of lifestyle treatment
(neighboring grey bars). The plot displays
quantitatively the status for each subject at
baseline (black bar), the change during
3 weeks of the treatment (difference between
grey and black bar) and the status (grey) after
3 weeks.
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in BMI and EPA/AA. Thus, contrary to the lifestyle inter-
vention, weight loss and changes in serum FAs after sur-
gery appear connected (Fig. 3).
Although to different degrees, all the patients show the
same pattern of reduced weight and EPA/AA after surgery.
Discussion
At baseline, the lifestyle patients had significantly higher
serum levels for all FAs compared to the matching group of
healthy subjects, except for EPA, DPA and 14:0 (Table 2).
This finding seems to contradict Ref. (7), where levels for
omega-3 FAs were found to be lower in subjects with obe-
sity than in healthy controls. However, that study compared
relative levels, not absolute levels as we do here. Relative
levels at baseline are lower in lifestyle patients for both EPA
and DHA also in our study, 1.1% vs. 1.4% for EPA and
2.5% vs. 2.9% for DHA.
A large reduction in absolute serum levels of FAs is
observed in patients after 3 weeks of lifestyle treatment at
RCHRC (Table 3). Serum TFA was reduced from a median
level at baseline, which was 45% higher to only 11–12%
above the levels in healthy subjects after 3 weeks of treat-
ment. A reduction is also observed in levels of EPA after
3 weeks but from a higher level in lifestyle patients than in
healthy controls, and the relative level is increased to 1.3%,
similar to the relative level in healthy subjects. The relative
level of serum DHA increases to 3.1%, which is also similar
to the level in healthy subjects. The main components that
might impact FA levels in our study were change in diet and
eating pattern and sessions of physical activity of a different
kind and duration. Perez-Cornago et al. (24) carried out a
weight loss intervention in a cohort of older adults (60  5
years) with overweight and obesity (27 ≤ BMI ≤ 35) by
means of caloric restriction. The participants were provided
































































































Figure 3 This figure shows the changes in
fatty acid (FA) pattern and body mass index
(BMI) after surgery. This selectivity ratio plot
(21,22) quantifies impact of bariatric surgery
on changes in absolute levels of serum FAs
and BMI 3 months after surgery. Confidence
bounds shown on bars correspond to two
standard deviations. Negative bar implies
reduction, while positive bar implies increase
















Figure 4 This figure shows the changes for the patients in the discriminating pattern displayed in Fig. 3. as positions (scores) of bariatric patients
(N = 14) just before (black bars) and 3 months after surgery (neighboring grey bars). The plot displays quantitatively the status for each subject at
baseline (black bar), the change 3 months after surgery (difference between grey and black bar) and the status (grey) 3 months after surgery.
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participants experienced 0.9%TWL (percent total weight
loss) per week, which is comparable to the lifestyle patients
at RCHRC (see below). Similar to our study, they observed
significant reduction in serum levels for the saturated FAs
14:0, 16:0, 18:0 and 24:0, the very abundant FAs 18:1 n-9
and LA and DGLA and no reduction in EPA. Contrary to
us, they observed a significant reduction in AA and DHA.
For AA, our analysis showed that changes in AA were on
the borderline of being significant, but another reason for
differences is that Perez-Cornago et al. did not correct their
31 univariate tests for multiple testing, providing very opti-
mistic significance levels.
Table 3 further reveals that after 3 weeks of intensive
lifestyle intervention, the serum levels of all the omega-3
FAs in patients are statistically equal to healthy controls at
P = 0.05. This is contrary to the observations after bariat-
ric surgery where serum ALA and EPA showed large reduc-
tions from preoperative levels during the weight loss
process after surgery (8).
Comparison of FA levels in patients 3 weeks after life-
style intervention with levels measured in bariatric
patients 3 months after surgery using the WMW test are
provided in Table 3. After correcting for multiple testing,
significant differences (P < 0.05) are observed for LA,
ALA, EPA and the EPA/AA ratio. They are all lower in
bariatric patients 3 months after surgery than in lifestyle
patients after 3 weeks of intervention. The impact of dif-
ferent rates in the weight loss process may, at least partly,
explain the lower levels of omega-3 FAs in bariatric
patients. Thus, after LSG surgery, the average %TWL is
1.3% weekly during the first 3 months (8). The lifestyle
patients experience 0.8%TWL per week during the first
3 weeks. The weight loss continues at almost the same
rate during the following 3 weeks at RCHRC,
i.e. 0.6–0.7%TWL per week. Thus, the lifestyle patients
lose weight at approximately half the rate of the bariatric
patients, although they are probably much more physi-
cally active with at least three training sessions 5 d a
week (14). The faster weight reduction in the bariatric
patients implies that they acquire a considerably larger
input from their own fat deposits than do the lifestyle
patients in order to compensate for larger energy short-
age. The FA profile available from these deposits are poor
in omega-3 FAs (12,13), which may lead to lower levels
of omega-3 in bariatric patients compared to lifestyle
patients. This can, however, be compensated by supple-
ments that increase serum omega-3 levels without influen-
cing the weight loss (25). Our analysis shows that
supplements are not necessary for lifestyle patients as long
as they follow the Nordic Nutrition Recommendations
(26) or similar dietary advice. For diets low in marine
omega-3, however, supplements may be necessary.
Thus, the differences in serum FA levels might be a
reflection of how fast and by which means weight
reduction is obtained in the two groups. The multivariate
analysis showed that the change in FA pattern and weight
loss were unrelated in the lifestyle patients (Fig. 1), but
highly associated in the bariatric patients (Fig. 3). Multi-
variate analysis of the changes in FA scores from baseline
and 3 weeks into the lifestyle intervention showed a non-
significant (P > 0.05) correlation coefficient of 0.35
between change in scores and %TWL. Thus, change in diet
and physical activity, and not weight loss, appears to be
the factors influencing the FA profiles in lifestyle patients,
while lowering of EPA/AA in bariatric patients may be
caused by reduced dietary input of omega-3 FAs.
Strengths and weaknesses
Comparison of lifestyle patients with both bariatric
patients and healthy controls from the same region at dif-
ferent intervention points provides a possibility for a broad
investigation. The determination of quantitative FA levels
is important as the omega-3 FAs are present in small
amounts, and relative levels may therefore be strongly
influenced by variation in a few abundant FAs. Use of mul-
tivariate analysis provides patterns that can easily be visua-
lized and assists the interpretation of intervention effects,
both of variables and subjects, and offers a complementary
picture to the univariate tests.
There are two weaknesses in our analysis. One is that
the lifestyle and bariatric patients included a few smokers,
while smokers were excluded in the healthy control. Recent
work (27) showed a reduction of EPA and DHA in smo-
kers due to less dietary input of fish. However, similar to
our previous work about the effect of serum lipoproteins
on the lifestyle patients (14), smoking showed no impact
on omega-3 levels maybe because of the low number of
smokers in our cohort. The lack of information on use of
omega-3 supplements at baseline and during intervention
for the patients may present a more serious weakness. For
the bariatric patients, this information was available, and
three patients were using omega-3 supplements. They all
had levels of EPA and DHA similar to the other bariatric
patients, probably because of small dosages of products
bought in grocery stores. Our assumption is that this result
is representative of the lifestyle patients and the healthy
controls too.
Conclusion
Intensive lifestyle intervention with a change in diet and
eating pattern, and increased physical activity, provides
slower rate of weight loss than does reduction of the gastric
volume by bariatric surgery. Reduction of FA serum levels
and weight loss are two almost uncorrelated effects of life-
style intervention. This is in contrast to gastric reduction
surgery, where changes in FA pattern and weight loss are
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associated and imply a shortage of omega-3 FAs and a
need for supplementation. Lifestyle patients can manage
without supplementation as long as they follow the Nordic
Nutrition Recommendations (26) or similar dietary advice.
For diets low in marine omega-3, however, supplements
may be needed.
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